Objective: To determine the influence of systemic lupus erythematosus (SLE), disease activity, and anticardiolipin antibodies (aCL) on lipid profile, in order to identify patients with high risk for coronary artery disease (CAD).
Methods: Fasting lipid profiles were performed in 36 consecutive female SLE patients without any therapy and 30 controls. Exclusion criteria were diabetes mellitus, CAD, liver or thyroid disease, ingestion of lipid-raising drugs, serum creatinine ≥ 1.5 mg/dl, and proteinuria ≥ 0.5 g/d. Disease activity was measured by SLEDAI.
Results: High levels of VLDL-C and TG and low levels of HDL-C, the 'lupus pattern', were observed in inactive SLE compared to controls (P < 0.05). Active disease enhanced this difference inducing a more striking increase in VLDL-C and TG levels and also a decrease in HDL-C and LDL-C levels compared to inactive SLE patients (P < 0.05), characterizing the 'active lupus pattern'. Moreover, a significant correlation was found between SLEDAI scores and all lipid fractions. Furthermore these lipid abnormalities were particularly associated with vasculitis. Lower HDL-C levels detected in IgG aCL+ patients compared to IgG aCL - patients were not confirmed by two-way analysis of variance which demonstrated that this difference was exclusively caused by disease activity.
Conclusions: Our findings suggest that SLE patients have a lipid profile abnormality which is aggravated by disease activity and may reside in a defect of VLDL metabolism. This pattern of dyslipoproteinemia may increase the risk of developing coronary artery disease.
Ginzler EM et al. A multicenter study of outcome in systemic lupus erythematosus. I. Entry variables as predictors of prognosis. Arthritis Rheum1982; 25: 601-611.
2.
Pistiner M. et al. Lupus erythematosus in the 1980s: a survey of 570 patients. Semin Arthritis Rheum1991; 21: 55-64.
3.
Seleznick MJ , Fries JFVariables associated with decreased survival in systemic lupus erythematosus. Semin Arthritis Rheum1991; 21: 73-80.
4.
Abu-Shakra M. , Urowitz MB, Gladman DD, Gough J.Mortality studies in systemic lupus erythematosus. Results from a single center. I. Causes of death. J Rheumatol1995; 22: 1259-1264.
5.
Urowitz MB et al. The bimodal mortality pattern of systemic lupus erythematosus . Am J Med1976; 60: 221-225.
6.
Ginzler E., Berg A.Mortality in systemic lupus erythematosus. J Rheumatol1987; 14 (Suppl. 13): 218-222.
7.
Rubin LA, Urowitz MB, Gladman DDMortality in systemic lupus erythematosus: the bimodal pattern revisited. Q J Med1985; 55: 87-98.
Hejtmancik MR , Wright JC, Quint R., Jennings FLThe cardiovascular manifestations of systemic lupus erythematosus. Am Heart J1964; 68: 119-130.
10.
Bulkley BH, Roberts WCThe heart in systemic lupus erythematosus and the changes induced in it by corticosteroid therapy: a study of 36 necropsy patients. Am J Med1975; 58: 243-264.
11.
Haider YS, Roberts WCCoronary arterial disease in systemic lupus erythematosus: quantification of degree of narrowing in 22 necropsy patients (21 women) aged 16 to 37 years . Am JMed1981; 70: 775-781.
12.
Badui E. et al. Cardiovascular manifestations in systemic lupus erythematosus. Prospective study of 100 patients. Angiology1985; 36: 431-441.
13.
Sturfelt G. et al. Cardiovascular disease in systemic lupus erythematosus. A study of 75 patients from a defined population. Medicine (Baltimore) 1992; 71: 216-223.
14.
Petri M., Perez-Gutthann S., Spence D., Hochberg MCRisk factors for coronary artery disease in patients with systemic lupus erythematosus . Am J Med1992; 93: 513-519.
15.
Petri M., Spence D., Bone LR, Hochberg MCCoronary artery disease risk factors in the Johns Hopkins Lupus Cohort: prevalence, recognition by patients, and preventive practices. Medicine (Baltimore) 1992; 71: 291-302.
16.
Leong KH, Koh ET, Feng PH, Boey MLLipid profiles in systemic lupus erythematosus. J Rheumatol1994; 21: 1264-1267.
17.
Appel GB et al. The hyperlipidemia of the nephrotic syndrome. Relation to plasma albumin concentration, oncotic pressure and viscosity. N Engl J Med1985; 312: 1544-1548.
18.
Brunzell JD et al. Prevalence of serum lipid abnormalities in chronic hemodialysis. Metabolism1977; 26: 903-910.
19.
Attman PO, Alaupovic P.Lipid and apolipoprotein profiles of uremic dyslipoproteinemia. Relation to renal function and dialysis. Nephron1991; 57: 401-410.
20.
Henkin Y., Como JA, Oberman A.Secondary dyslipidemia. Inadvertent effects of drugs in clinical practice . JAMA1992; 267: 961-968.
21.
Glueck CJ et al. Acquired type I hyperlipoproteinemia with systemic lupus erythematosus, dysglobulinemia and heparin resistance. Am J Med1969; 47: 318-324.
22.
Glueck CJ et al. A new mechanism of exogenous hyperglyceridemia. Ann Intern Med1969; 71: 1051-1062.
23.
Pauciullo P. , De Simone B., Rubba P., Mancini M.A case of association between type I hyperlipoproteinemia and systemic lupus erythematosus (SLE). Effects of steroid treatment. J Endocrinol Invest1986; 9: 517-520.
24.
Stem MP, Kolterman OG, McDevitt H., Reaven GMAcquired type 3 hyperlipoproteinemia. Report of three cases associated with systemic lupus erythematosus and diabetic ketoacidosis. Arch Intern Med1972; 130: 817-821.
25.
Alverson DC , Chase HPSystemic lupus erythematosus in childhood presenting as hyperlipoproteinemia. J Pediatr1977; 91: 72-75.
26.
Tan EM et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum1982; 25: 1271-1277.
27.
Bombardier C. et al. A disease activity index for lupus patients . Arthritis Rheum1992; 35: 630-640.
28.
Siedel J., Hägele EO, Ziegenhorn J., Wahlefeld AWReagent for the enzymatic determination of serum total cholesterol with improved lipolytic efficiency. Clin Chem1983; 29: 1075-1080.
29.
Fossati P., Prencipe L.Serum triglycerides determined colorimetrically with an enzyme that produces hydrogen peroxide. Clin Chem1982; 28: 2077-2080.
30.
Warnick GR, Cheung MC, Albers JJComparison of current methods for high-density lipoprotein cholesterol quantification . Clin Chem1979; 25: 596-604.
31.
Friedewald WT , Levy RI, Fredrickson DSEstimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge . Clin Chem1972; 18: 499-502.
32.
Gharavi AE, Harris EN, Asherson RA, Hughes Grv.Anticardiolipin antibodies: isotype distribution and phospholipid specificity . Ann Rheum Dis1987; 46: 1-6.
33.
Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. National Cholesterol Education Program: second report of the expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel II). Circulation1994; 89: 1329-1445.
34.
Castelli WPCardiovascular disease in women. Am J Obstet Gynecol1988; 158: 1553-1560.
35.
Brown WVLipoprotein disorders in diabetes mellitus. Med Clin North Am1994; 78: 143-161.
Thompson GR et al. Defects of receptor-mediated low density lipoprotein catabolism in homozygous familial hypercholesterolemia and hypothyroidism . Proc Soc Natl Acad Sci USA1981; 78: 2591-2595.
38.
Haskell WL et al. The effect of cessation and resumption of moderate alcohol intake on serum high-density-lipoprotein subfractions. N Engl J Med1984; 310: 805-810.
39.
Heiss G. et al. Lipoprotein-cholesterol distributions in selected north american populations: The Lipid Research Clinics Program Prevalence Study. Circulation1980; 61: 302-315.
40.
Kannel WB, Hjortland MC, McNamara PM, Gordon T.Menopause and risk of cardiovascular disease. The Framingham Study. Ann Intern Med1976; 85: 447-452.
41.
Denke MA, Sempos CT, Grundy SMExcess body weight. An under-recognized contributor to dyslipidemia in white american women. Arch Intern Med1994; 154: 401-410.
42.
Ettinger WH , Goldberg AP, Applebaum-Bowden D., Hazzard WRDyslipoproteinemia in systemic lupus erythematosus. Effects of corticosteroids. Am J Med1987; 83: 503-508.
43.
Ettinger WH , Hazzard WRElevated apolipoprotein-B levels in corticosteroid-treated patients with systemic lupus erythematosus. J Clin Endocrinol Metab1988; 67: 425-428.
44.
Ilowite NT, Samuel P., Ginzler E., Jacobson MSDyslipoproteinemia in pediatric systemic lupus erythematosus. Arthritis Rheum1988; 31: 859-863.
45.
Wallace DJ et al. Cholesterol-lowering effect of hydroxychloroquine in patients with rheumatic disease: reversal of deleterious effects of steroids on lipids . Am J Med1990; 89: 322-326.
46.
MacGregor AJ et al. Fasting lipids and anticardiolipin antibodies as risk factors for vascular disease in systemic lupus erythematosus. Ann Rheum Dis1992; 51: 152-155.
47.
Hodis HN, Quismorio FP, Wickham E., Blankenhorn DHThe lipid, lipoprotein, and apolipoprotein effects of hydroxychloroquine in patients with systemic lupus erythematosus. J Rheumatol1993; 20: 661-665.
48.
Petri M., Lakata C., Magder L., Goldman D.Effect of prednisone and hydroxychloroquine on coronary artery disease risk factors in systemic lupus erythematosus: a longitudinal data analysis. Am J Med1994; 96: 254-259.
49.
Gordon T. et al. High density lipoprotein as a protective factor against coronary heart disease. Am J Med1977; 62: 707-714.
50.
Castelli WP et al. Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study. JAMA1986; 256: 2835-2838.
51.
Jacobs DR et al. High density lipoprotein cholesterol as a predictor of cardiovascular disease mortality in men and women: the Follow-up Study of the Lipid Research Clinics' Prevalence Study. Am J Epidemiol1990; 131: 32-47.
52.
Castelli WPThe triglyceride issue: a view from Framingham . Am Heart J1986; 112: 432-437.
53.
Bass KM, Newschaffer CJ, Klag MJ, Bush TLPlasma lipoprotein levels as predictors of cardiovascular death in women. Arch Intern Med1993; 153: 2209-2216.
54.
Schaefer EJ et al. Plasma triglycerides in regulation of HDLcholesterol levels. Lancet1978; ii: 391-392.
55.
Castelli WPCardiovascular disease in women. Am J Obstet Gynecol1988; 158: 1553-1560.
56.
Richards GE , Grundy SM, Cooper K.Influence of plasma triglycerides on lipoprotein patterns in normal subjects and in patients with coronary artery disease. Am J Cardiol1989; 63: 1214-1220.
57.
Stender S., Zilversmit DBTransfer of plasma lipoprotein components and plasma proteins into aortas of cholesterol-fed rabbits: molecular size as a determinant of plasma lipoprotein influx. Arteriosclerosis1981 ; 1: 28-49.
58.
Chait A., Brazg RL, Tribble DL, Krauss RMSusceptibility of small, dense, low-density lipoproteins to oxidative modification in subjects with the atherogenic lipoprotein phenotype, pattern B. Am J Med1993; 94: 350-356.
59.
Vaarala O. et al. Crossreaction between antibodies to oxidised low-density lipoprotein and to cardiolipin in systemic lupus erythematosus. Lancet1993; 341: 923-925.
60.
Mizutani H. et al. Monoclonal anticardiolipin autoantibodies established from the (New Zealand white x BXSB)F1 mouse model of antiphospholipid syndrome cross-react with oxidized low-density lipoprotein. Arthritis Rheum1995; 38: 1382-1388.
61.
Vaarala O.Antiphospholipid antibodies and atherosclerosis. Lupus1996; 5: 442-447.
62.
Borba EF et al. Lipoprotein(a) levels in systemic lupus erythematosus. J Rheumatol1994; 21: 220-223.
63.
Petri M., Miller J., Ebert RF, Goldman D.Lipoprotein(a) [Lp(a)] is predictive of myocardial infarction in SLE. Arthritis Rheum1995; 38 (suppl): S220 (abstract 404).
64.
Lahita RG, Rivkin E., Cavanagh I., Romano P.Low levels of total cholesterol, high-density lipoprotein, and apolipoprotein A1 in association with anticardiolipin antibodies in patients with systemic lupus erythematosus. Arthritis Rheum1993; 36: 1566-1574.
65.
Ginsberg HNLipoprotein metabolism and its relationship to atherosclerosis. Med Clin North Am1994 ; 78: 1-20.
66.
Deckelbaum RJ et al. Plasma triglyceride determines structure-composition in low and high density lipoproteins. Arteriosclerosis1984; 4: 225-231.
67.
Falko JM et al. Hyperlipoproteinemia and multifocal neurologic dysfunction in systemic lupus erythematosus. J Pediatr1979 ; 95: 523-529.
Beutler BA et al. Purification of cachechtin, a lipoprotein lipase-suppressing hormone secreted by endotoxin induced raw 264.7 cells. J Exp Med1985; 161: 984-995.
70.
Kurzrock R. et al. Recombinant gamma-interferon induced hypertriglyceridemia and inhibits post-heparin lipase activity in cancer patients . J Exp Med1986; 164: 1093-1101.
71.
Rozenzweig IB et al. Plamsa lipoprotein changes in humans induced by beta interferon. Atherosclerosis1987; 67: 261-267.
Lazarevic MB et al. Antilipoprotein antibodies in rheumatoid arthritis. Semin Arthritis Rheum1993; 22: 385-391.
74.
Merrill JT, Rivkin E., Shen C., Lahita RGSelection of a gene for apolipoprotein A1 using autoantibodies from a patient with systemic lupus erythematosus. Arthritis Rheum1995; 38: 1655-1659.
75.
Berman M. et al. Metabolism of apoB and apoC lipoproteins in man: kinetic studies in normal and hyperlipoproteinemic subjects. J Lipid Res1978; 19: 38-55.
76.
Sakai J. et al. Structure, chromosome location, and expression of the human very low density lipoprotein receptor gene. J Biol Chem1994; 269: 2173-2182.
77.
Jingami H., Yamamoto T. TheVLDL receptor: wayward brother of the LDL receptor. Curr Opin Lipidol1995; 6: 104-108.
